Pristinamycin in the Treatment of MSSA Bone and Joint Infection

Civil Hospices of Lyon

Status: Completed

Conditions: Bone and Joint Infection; Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection

Study type: Observational

Funder types: Other

Identifiers

NCT03177343

69HCL17_0384

Details and patient eligibility

About

Staphylococcus aureus represents the leading pathogen implicated in bone and joint infection (BJI), usually requiring prolonged combination antimicrobial therapy, which may be particularly challenging in the case of MDR bacteria and/or for patients with multiple drug intolerance. In the absence of new well-tolerated oral antistaphylococcal drugs, older antibiotics must be considered, such as the pristinamycin.

However, pristinamycin is not currently licensed for treatment of staphylococcal BJI and lack of clinical data prevents it from being considered as a reliable alternative therapeutic option in current guidelines.

The aim of this study is to evaluate pristinamycin (efficacy and tolerance) in the treatment of MSSA bone and joint infection (BJI).

Enrollment: 102 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Inclusion Criteria:
• All patients receiving pristinamycin as a part of treatment for an MSSA BJI and followed up between 2001 and 2011 in the infectious diseases department of Hospices Civils de Lyon (HCL)
• Exclusion Criteria:
• Patients with BJI related to diabetic foot or decubitus ulcer